←
Liam Galvin1,531 posts
Liam Galvin avatar

Liam Galvin

@IPFthurles

Board Member - Irish Lung Fibrosis Association (@ILFA_Ireland) and European Pulmonary Fibrosis Federation (@EU_IPFF), Patient Co-Chair @ErnLung,

◷ Joined September 2015▧ 223 Photos and videos
Rare Disease Clinical Trial Network, Ireland avatar
⟳ Liam Galvin retweeted
Rare Disease Clinical Trial Network, Ireland@rare_trial·Nov 2

It’s conference week! This Thursday, the rare disease research community will come together at University College Dublin for a full day of research, lived experience, clinical trial updates, innovation and discussion.

Post attachment
ERS publications avatar
⟳ Liam Galvin retweeted
ERS publications@ERSpublications·Mar 8

European Respiratory Journal: Fan-to-face therapy is a simple, feasible, low-cost, low-resource nonpharmacological approach to reduce exertional breathlessness during exercise training in adults with chronic lung disease bit.ly/4oMpcbX

Post attachment
Liam Galvin avatar
Liam Galvin@IPFthurles·18 Nov 2025

Great news for the patient community

Approved today: the first ever approved therapy for bronchiectasis in Europe Congratulations investigators, patients and Insmed Science changes lives European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union - Nov 18, 2025 investor.insmed.com/2025-11-…

ERS avatar
⟳ Liam Galvin retweeted
ERS@EuroRespSoc·24 Oct 2025

🚨Free educational opportunity: apply now for the ERN-LUNG Academy 2026 We are calling on medical professionals across the EU to apply for the opportunity to develop their knowledge of rare respiratory diseases. Apply by 30 November, 2025 – learn more: bit.ly/3L6KjqY

Post attachment
European Lung Foundation avatar
⟳ Liam Galvin retweeted
European Lung Foundation@EuropeanLung·28 Sep 2025

The first patient-centered studio session at #ERSCongress! 💙 Co-chaired by patient representatives Helen Parks and Steve Jones, this busy session explored why many patients struggle to access pulmonary rehabilitation globally.

Post attachment
Trevi Therapeutics avatar
⟳ Liam Galvin retweeted
Trevi Therapeutics@TreviThera·2 Jun 2025

We are pleased to share the positive topline results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough.   Join our conference call today, June 2nd, at 8:30 a.m. ET.  Read the press release: ow.ly/MCzh50W2spG $TRVI

Pilar Rivera-Ortega avatar
⟳ Liam Galvin retweeted
Pilar Rivera-Ortega@PilarRiveraOrt1·4 Jun 2025

Dear ILD community, You are cordially invited to this webinar organized by @RespirEffect (REG) tomorrow June 5th at 4 pm BST - UK time (5 pm CEST) 👇 #Screening #EarlyDiagnosis #ILD #PulmonaryFibrosis #PrimaryCare 🫁🌎

REG WEBINARS - REMINDER TO REGISTER 📢 The next REG Webinar is: Screening and early diagnosis of Interstitial Lung Disease: starting the process from Primary Care 🗓️Thursday 5th June 2025 from 5 to 6PM CET 🖥️ Register @ events.teams.microsoft.com/e… #rwe #ild #ipf

Post attachment
Phil Molyneaux avatar
⟳ Liam Galvin retweeted
Phil Molyneaux@drphilmol·2 Jun 2025

Fantastic news for all our patients with IPF who suffer with cough! An overall 43% reduction in cough counts, similar improvement in patient reported cough and benefits seen in 2 weeks. We look forward to the phase 3 study!

We are pleased to share the positive topline results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough.   Join our conference call today, June 2nd, at 8:30 a.m. ET.  Read the press release: ow.ly/MCzh50W2spG $TRVI

Toby Maher avatar
⟳ Liam Galvin retweeted
Toby Maher@TobyMMaher·18 May 2025

Great to see publication of the first positive phase 3 trial in patients with IPF. This represents an important step forward in the treatment of this terrible disease. #cureipf

NEJM@NEJM18 May 2025

Presented at #ATS2025: In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: nej.md/4mgWcIU @atscommunity

Post attachment